ISSN E 2959-3751
ISSN P 2959-3743

RICOS BIOLOGY JOURNAL

Vol. 3, no. 10
October, 2025

https://ricosbiology.net
https://ricospublisher.us
info@ricosbiology.net

Ricos Biology Journal, October, 2025, Vol. 3 (10) 1-26.
www.ricosbiology.net/Vol.3(8)/August-2025/1-32

RESEARCH ARTICLE
Open Access

Table of contents

Review article

The Cure That Harms: How Bad Medication for Chronic Illness Fuels a Silent Epidemic of Superbugs

Abouelhag H. A.

Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Corresponding author:*Abouelhag H. A.* **E-mail:**drabouelhag5@gmail.com

Received: 29-08-2025 **Accepted:** 24-09-2025 **Published online:** 30-10-2025

DOI: https://doi.org/10.33687/ricosbiol.03.10.84

Abstract

The global rise in chronic diseases represents a significant public health burden. While the primary management of these conditions is paramount, a growing body of evidence highlights a dangerous and often overlooked consequence: the increased risk of secondary bacterial infections. This risk is profoundly exacerbated by the inappropriate medication of the underlying chronic disease. Inappropriate medication includes the misuse of antibiotics, immunosuppressive agents, corticosteroids, and broad-spectrum therapies that disrupt the microbiome. These pharmacological missteps can lead to immunosuppression, microbial dysbiosis, and the selection of drug-resistant pathogens, creating a fertile ground for secondary infections. This review synthesizes current literature to explore the mechanisms including immunosuppression, microbiome disruption, and antimicrobial resistance by which poor pharmacologic management of chronic diseases such as diabetes, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and inflammatory bowel disease predisposes patients to serious secondary bacterial infections, with a special focus on devastating bone and joint complications. It also discusses the clinical implications, common causative pathogens, and proposes strategies for mitigation, emphasizing antimicrobial stewardship and personalized medicine to break this dangerous cycle.

Keywords: secondary bacterial infection, chronic disease management, antimicrobial resistance, superbugs, osteomyelitis, immunosuppression, microbiome, antimicrobial stewardship.

Introduction

Chronic diseases, including diabetes mellitus, chronic obstructive pulmonary disease (COPD), autoimmune disorders, and cardiovascular diseases, are the leading causes of mortality and morbidity worldwide (World Health Organization, 2022). The management of these conditions is often long-term and complex, relying on a regimen of pharmacotherapies to control symptoms, slow progression, and maintain quality of life. However, the very medications used to manage these diseases, when prescribed or used inappropriately, can have unintended and severe consequences (Feldstein *et al*., 2021).

Among the most serious of these consequences is the development of secondary bacterial infections and the fueling of the antimicrobial resistance (AMR) crisis. These infections occur subsequent to, and are facilitated by, an initial condition or its treatment. The link between inappropriate medication practices such as the overprescription of antibiotics, prolonged or high-dose corticosteroid use, and indiscriminate application of immunosuppressants and the emergence of "superbugs" is a critical clinical challenge (Murray *et al*., 2022). This review aims

to comprehensively examine the pathophysiological mechanisms, identify high-risk chronic diseases and common pathogens with a dedicated focus on severe bone and joint infections and discuss integrative strategies to prevent this iatrogenic complication.

1. Pathophysiological Mechanisms Linking Bad Medication to Secondary Infections

1.1. Iatrogenic Immunosuppression

Many chronic inflammatory and autoimmune diseases are managed with immunosuppressive agents. While these are necessary to control the underlying disease, their inappropriate use either in dosage, duration, or patient selection can lead to profound immunosuppression.

- **Corticosteroids:** Glucocorticoids are a cornerstone of treatment for conditions like rheumatoid arthritis, lupus, and asthma. However, high-dose or long-term use impairs neutrophil function, inhibits macrophage activity, and suppresses dendritic cell maturation, crippling both innate and adaptive immunity (Liu *et al*., 2013). A recent large-scale study confirmed that even moderate-dose glucocorticoid therapy (>5mg prednisolone-equivalent/day) is associated with a dose-dependent increase in the risk of hospitalization for serious infection (Pujades-Rodriguez *et al*., 2020).
- **Biologics and DMARDs:** Tumor Necrosis Factor-alpha (TNF-α) inhibitors and other biologics (e.g., JAK inhibitors) used for rheumatoid arthritis and inflammatory bowel disease are associated with an increased risk of serious and opportunistic infections. Recent real-world data underscores that the risk is highest in the initial months of therapy and when combined with other immunosuppressants, highlighting the need for careful patient selection and monitoring (Rutherford *et al*., 2022).

1.2. Disruption of the Microbiome and Dysbiosis

The human microbiome, particularly the gut and respiratory microbiomes, plays a crucial role in training the immune system and providing colonization resistance against pathogens.

- **Broad-Spectrum Antibiotics:** The inappropriate use of antibiotics remains a primary driver of dysbiosis. Recent research has detailed how antibiotics cause a rapid loss of microbial diversity and metabolic function, allowing for the expansion of pathogenic, often multidrug-resistant organisms (MDROs) like *Clostridioides difficile*, vancomycin-resistant Enterococci (VRE), and carbapenem-resistant Enterobacteriaceae (CRE) (Ng *et al*., 2023). This is particularly detrimental in chronically ill patients who experience repeated exposures.
- **Non-Antibiotic Drugs:** The concept of "non-antibiotic drugs" impacting the microbiome has gained substantial traction. A landmark study demonstrated that a wide range of commonly prescribed drugs, including metformin, proton pump inhibitors, and atypical antipsychotics, have robust, class-specific effects on the gut microbiome composition and can thereby modulate patient susceptibility to infection (Vich Vila *et al*., 2020).

1.3. Induction of Antimicrobial Resistance (AMR)

Inappropriate medication, especially antibiotic overuse and misuse, is the single most significant driver of antimicrobial resistance. In the context of chronic disease management, this creates a vicious cycle.

- **Selective Pressure and Resistance Gene Transfer:** Beyond simple selection, recent metagenomic studies show that antibiotic pressure facilitates the horizontal transfer of resistance genes between commensal and pathogenic bacteria within the dysbiotic microbiome (Larsson and Flach, 2022).
- **Treatment Failure:** When a secondary infection occurs, empirical antibiotic therapy may fail due to this pre-existing resistance. The 2022 Global Burden of Disease report on AMR

attributed 1.27 million deaths directly to bacterial AMR in 2019, underscoring the lethal consequences of ineffective therapy (Murray *et al*., 2022).

2. High-Risk Chronic Diseases and Associated Secondary Infections

2.1. Diabetes Mellitus

Poor glycemic control itself is a state of immune dysfunction, impairing neutrophil chemotaxis and phagocytosis. Inappropriate medication exacerbates this.

• **Scenario:** Failure to manage hyperglycemia effectively, coupled with inappropriate antibiotic prescribing for minor skin infections, can lead to severe secondary infections. Recent evidence shows that SGLT2 inhibitor use, while beneficial for glycemic and cardiovascular control, may be associated with a slightly increased risk of genitourinary infections and Fournier's gangrene if not prescribed with appropriate patient counseling and monitoring (Bersoff-Matcha *et al*., 2019).

• **Common Pathogens:** *S. aureus* (including MRSA), *Streptococcus* spp., and gram-negative bacilli.

2.2. Chronic Obstructive Pulmonary Disease (COPD)

COPD patients experience frequent acute exacerbations, many of which are viral or non-infectious.

• **Scenario:** The widespread practice of prescribing antibiotics for all exacerbations promotes airway microbiome disruption. A 2021 study found that repeated antibiotic courses in COPD lead to a progressive decline in airway microbial diversity and enrichment with proteobacteria, including *P. aeruginosa*, which is associated with more frequent future exacerbations (Dickens *et al*., 2021).

• **Common Pathogens:** *H. influenzae*, *S. pneumoniae*, *M. catarrhalis*, *P. aeruginosa*.

2.3. Autoimmune and Inflammatory Diseases (RA, IBD, Lupus)

As discussed, the main risk stems from immunosuppressive therapy.

• **Scenario:** The use of JAK inhibitors for RA and other conditions has been linked in post-marketing studies to an increased risk of herpes zoster and serious opportunistic infections, necessitating careful risk-benefit analysis (Cohen *et al*., 2021).

• **Common Pathogens:** *Mycobacterium tuberculosis*, *Listeria monocytogenes*, *S. aureus*, and opportunistic gram-negative bacteria.

2.4. Devastating Bone and Joint Complications

The skeletal system is a frequent and devastating site for secondary bacterial infections, which are notoriously difficult to treat and often lead to long-term disability.

• **Diabetic Foot Osteomyelitis:** The diabetic foot ulcer is a primary pathway for bone infection. Inappropriate medication is a critical factor:

  ○ **Poor Glycemic Control:** Failure to manage hyperglycemia impairs immune function and antibiotic delivery (Lázaro-Martínez *et al*., 2021).

  ○ **Inappropriate Antibiotic Use:** Short, narrow-spectrum courses for ulcers select for MDROs. Prior antibiotic exposure is a key risk factor for MDR osteomyelitis (Uçkay *et al*., 2020).

  ○ **Lack of Source Control:** Relying on antibiotics without surgical debridement allows biofilms to form on necrotic bone, making eradication nearly impossible (Masters *et al*., 2021).

• **Septic Arthritis in Rheumatologic Diseases:** Patients with RA are at high risk for joint infections, amplified by their therapies.

- **Corticosteroids and Biologics:** These agents mask signs of infection and depress local immune surveillance. JAK inhibitors, in particular, are associated with a significant increase in serious infections, including musculoskeletal ones (Xie *et al*., 2022). Symptoms can be mistaken for an RA flare, leading to dangerous delays (Talsania *et al*., 2021).

• **Vertebral Osteomyelitis:** This often arises from hematogenous spread in patients with chronic conditions.

- **Mechanism:** Inadequate treatment of a primary infection (e.g., UTI, catheter-site infection) due to inappropriate antibiotic selection can lead to bacteremia and seeding of the spine. A history of recurrent infections treated with multiple antibiotics is a predictor for complex osteomyelitis (Barton *et al*., 2023).

2.5. Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD):

Uremia in CKD causes immune dysfunction. Medication mismanagement adds another layer of risk.

• **Scenario:** Inappropriate dosing of antibiotics without renal adjustment remains a common problem. A recent systematic review highlighted that suboptimal dosing in ESRD patients is a significant predictor of treatment failure and the emergence of resistance (Sakharkar *et al*., 2022).

• **Common Pathogens:** *S. aureus* (including MRSA), VRE, and ESBL-producing gram-negative rods.

3. Clinical and Public Health Implications

The consequences extend beyond the individual patient. Secondary infections lead to:

- **Increased morbidity and mortality,** with AMR now being a leading cause of death globally (Murray *et al*., 2022).
- **Prolonged hospitalizations and increased healthcare costs,** placing a massive strain on health systems (Nelson *et al*., 2021).
- **Acceleration of the global AMR crisis,** rendering first-line antibiotics ineffective.
- **Complex treatment dilemmas,** where the need to treat the chronic disease must be balanced against the risk of unleashing an uncontrollable infection.

4. Mitigation and Future Directions

Breaking the cycle requires a multi-pronged approach:

- **Antimicrobial Stewardship Programs (ASPs):** The integration of ASPs into outpatient settings, including specialty clinics for chronic diseases, is a critical and evolving frontier. The use of clinical decision support systems within electronic health records can significantly reduce inappropriate prescribing (Buehrle *et al*., 2020).
- **Precision Medicine and Biomarkers:** Utilizing biomarkers like procalcitonin to guide antibiotic therapy in COPD and other respiratory conditions continues to be validated as an effective strategy to reduce unnecessary exposure (Huang *et al*., 2021).
- **Vaccination:** Ensuring patients with chronic diseases are up-to-date with vaccinations (e.g., pneumococcal, influenza, COVID-19) is more important than ever to prevent primary infections that lead to secondary bacterial complications.
- **Microbiome-Targeted Interventions:** Research into microbiome-based therapeutics is advancing. The use of targeted, narrow-spectrum antibiotics and fecal microbiota transplantation for recurrent C. difficile infection is a proven model that may be expanded to other dysbiosis-associated conditions in the future (Ianiro *et al*., 2020).

Conclusion

The management of chronic diseases is a delicate balancing act. Inappropriate medication practices, particularly concerning antibiotics, corticosteroids, and immunosuppressants, directly undermine this balance by increasing the susceptibility to severe secondary bacterial infections and fueling the silent epidemic of superbugs. This occurs through mechanisms of iatrogenic immunosuppression, microbiome disruption, and the fueling of antimicrobial resistance. The recent literature solidifies these links and quantifies the substantial associated morbidity and mortality, with devastating complications such as osteomyelitis representing a final common pathway of therapeutic failure. Clinicians must be vigilant in applying the principles of antimicrobial stewardship and personalized medicine. A proactive, holistic approach that considers the patient's immune status, microbiome health, and local resistance patterns is essential to safely manage the chronic disease while preventing the devastating consequences of a secondary infection. The goal is not to withhold necessary treatment but to optimize it, ensuring that the cure does not become a source of greater harm.

References

Barton, K. D., Kavanagh, N., O'Connell, B., O'Toole, M., O'Sullivan, T., and O'Brien, F. J. (2023). Risk factors for treatment failure in patients with chronic osteomyelitis: A retrospective cohort study. *Journal of Bone and Joint Infection, 8*(1), 35-44. https://doi.org/10.5194/jbji-8-35-2023

Bersoff-Matcha, S. J., Chamberlain, C., Cao, C., Kortepeter, C., and Chong, W. H. (2019). Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. *Annals of Internal Medicine, 170*(11), 764–769. https://doi.org/10.7326/M19-0085

Buehrle, D. J., Wagener, M. M., Nguyen, M. H., and Clancy, C. J. (2020). Impact of an antimicrobial stewardship program-bundled initiative utilizing advanced molecular diagnostics for carbapenem-resistant Gram-negative bacterial infections. *Open Forum Infectious Diseases, 7*(7), ofaa227. https://doi.org/10.1093/ofid/ofaa227

Cohen, S. B., Koenig, A., Wang, L., Kwok, K., Mebus, C. A., and Riese, R. (2021). The safety profile of tofacitinib in patients with rheumatoid arthritis: A post-hoc analysis of laboratory parameters and infectious events. *Rheumatology and Therapy, 8*(1), 281-296. https://doi.org/10.1007/s40744-020-00267-8

Dickens, J. A., Miller, B. E., Edwards, L. D., Silverman, E. K., Lomas, D. A., and Tal-Singer, R.; ECLIPSE Investigators. (2021). COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. *Respiratory Research, 22*(1), 86. https://doi.org/10.1186/s12931-021-01682-3

Feldstein, D. A., Ogden, R., Hohmann, S. F., and Kopp, B. J. (2021). A multifaceted antimicrobial stewardship program for the treatment of uncomplicated cystitis in the emergency department. *Journal of Pharmacy Practice, 34*(4), 545-550. https://doi.org/10.1177/0897190019876498

Huang, D. T., McCreary, E. K., Bariola, J. R., Wadas, R. J., Kip, K. E., Marroquin, O. C., Collins, T., Schmid, A., Yealy, D. M., and Angus, D. C. (2021). The efficacy and safety of procalcitonin guidance in antibiotics discontinuation in sepsis: A systematic review and meta-analysis of randomized controlled trials. *Critical Care Medicine, 49*(7), 1119-1131. https://doi.org/10.1097/CCM.0000000000004947

Ianiro, G., Mullish, B. H., Kelly, C. R., Kassam, Z., Kuijper, E. J., Ng, S. C., and Zhang, F. (2020). Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. *Gut, 69*(9), 1555-1563. https://doi.org/10.1136/gutjnl-2020-321829

Larsson, D. G. J., and Flach, C. F. (2022). Antibiotic resistance in the environment. *Nature Reviews Microbiology, 20*(5), 257–269. https://doi.org/10.1038/s41579-021-00649-x

Lázaro-Martínez, J. L., García-Madrid, M., García-Álvarez, Y., and Álvaro-Afonso, F. J. (2021). The role of biomarkers in the diagnosis and management of diabetic foot osteomyelitis: A systematic review. *Journal of Clinical Medicine, 10*(14), 3027. https://doi.org/10.3390/jcm10143027

Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., and Kim, H. (2013). A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy, Asthma, and Clinical Immunology, 9*(1), 30. https://doi.org/10.1186/1710-1492-9-30

Masters, E. A., Ricciardi, B. F., Bentley, K. L. M., Moriarty, T. F., Schwarz, E. M., and Muthukrishnan, G. (2021). Skeletal infections: Microbial pathogenesis, immunity and clinical management. *Nature Reviews Microbiology, 20*(7), 385–400. https://doi.org/10.1038/s41579-022-00686-0

Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... and Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet, 399*(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

Nelson, R. E., Hatfield, K. M., Wolford, H., Samore, M. H., Scott, R. D., Reddy, S. C., ... and Baggs, J. (2021). National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. *Clinical Infectious Diseases, 72*(Suppl 1), S17–S26. https://doi.org/10.1093/cid/ciaa1581

Ng, K. M., Aranda-Díaz, A., Tropini, C., Frankel, M. R., Van Treuren, W., O'Laughlin, C. T., ... and Sonnenburg, J. L. (2023). Recovery of the gut microbiota after antibiotics depends on host diet, community context, and environmental reservoirs. *Cell Host and Microbe, 31*(4), 519-533.e6. https://doi.org/10.1016/j.chom.2023.02.008

Pujades-Rodriguez, M., Morgan, A. W., Cubbon, R. M., and Wu, J. (2020). Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases. *Circulation, 142*(11), 1059-1062. https://doi.org/10.1161/CIRCULATIONAHA.119.044794

Rutherford, A. I., Subesinghe, S., Hyrich, K. L., and Galloway, J. B. (2022). Serious infection across biologic-treated patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Annals of the Rheumatic Diseases, 81*(4), 542-548. https://doi.org/10.1136/annrheumdis-2021-221304

Sakharkar, P., Bounthavong, M., and Hirsch, J. D. (2022). A systematic review of the impact of antimicrobial dosing strategies on resistance development in patient-level models. *Infection and Drug Resistance, 15*, 983–996. https://doi.org/10.2147/IDR.S347641

Talsania, M., Scofield, R. H., and Menzies, H. (2021). Septic arthritis in inflammatory arthritis: A challenging diagnostic dilemma. *Therapeutic Advances in Musculoskeletal Disease, 13*, 1759720X211015003. https://doi.org/10.1177/1759720X211015003

Uçkay, I., Gariani, K., Dubois-Ferriere, V., Suvà, D., and Lipsky, B. A. (2020). Diabetic foot infections: Recent advances and future prospects. *Diabetes Therapy, 11*(11), 2527–2545. https://doi.org/10.1007/s13300-020-00930-x

Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., ... and Weersma, R. K. (2020). Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. *Nature Communications, 11*(1), 362. https://doi.org/10.1038/s41467-019-14177-z

World Health Organization. (2022, June 22). *Noncommunicable diseases*. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

Xie, W., Huang, Y., Xiao, S., Sun, X., Fan, Y., and Zhang, Z. (2022). Risk of serious infections in rheumatoid arthritis patients treated with biologics and tofacitinib: A systematic review and meta-analysis. *Frontiers in Immunology, 13*, 858757. https://doi.org/10.3389/fimmu.2022.858757

Review article

The Unique Challenge: Why Microbes Struggle to Develop Resistance to Antimicrobial Peptides

Abouelhag H. A.

Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Corresponding author:*Abouelhag H. A.* **E-mail:**drabouelhag5@gmail.com

Received: 29-08-2025 **Accepted:** 24-09-2025 **Published online:** 30-10-2025

DOI: https://doi.org/10.33687/ricosbiol.03.10.85

Abstract

The escalating crisis of antimicrobial resistance (AMR) threatens to unravel a century of medical progress. Conventional antibiotics, with their specific, single-target mechanisms, are increasingly rendered ineffective, necessitating the urgent development of novel therapeutic strategies. Antimicrobial Peptides (AMPs), fundamental components of the innate immune system across all kingdoms of life, have emerged as promising candidates. A pivotal advantage of AMPs over traditional antibiotics is the perceived difficulty for microbes to develop robust resistance against them. This review delves into the mechanistic underpinnings of this phenomenon, exploring the unique mode of action of AMPs, the fitness costs associated with resistance mechanisms, and the evolutionary trade-offs that constrain microbial adaptation. While acknowledging that resistance is not impossible, we argue that the inherent properties of AMPs present a significantly higher and more complex barrier for resistance development compared to conventional drugs.

Keywords: antimicrobial peptides, antimicrobial resistance, drug development, membrane disruption, fitness cost, innate immunity, host defense peptides, evolutionary trade-offs.

Introduction

The AMR Crisis and the Promise of AMPs

The discovery of antibiotics revolutionized medicine, but their widespread and often indiscriminate use has selected for resistant pathogens, creating a global health emergency (World Health Organization, 2024). Conventional antibiotics typically inhibit specific, essential bacterial processes, such as cell wall synthesis (e.g., β-lactams), protein synthesis (e.g., macrolides), or DNA replication (e.g., fluoroquinolones). A single point mutation in the target gene can often confer high-level resistance, which can be rapidly disseminated through horizontal gene transfer (Blair *et al*., 2015).

In this landscape, Antimicrobial Peptides (AMPs) offer a paradigm shift. These small, typically cationic and amphipathic molecules are ubiquitous in nature, serving as first-line defenders in plants, animals, and humans (Zasloff, 2002). Their potential as next-generation therapeutics lies not only in their potent, broad-spectrum activity but, crucially, in the formidable challenges they pose to the evolution of resistance.

1. The Mechanistic Basis: A Multi-Pronged Attack Unlike Any Other

The primary reason for the low propensity for resistance is the fundamental difference in the mechanism of action between AMPs and traditional antibiotics.

1.1. Membrane Disruption: The Primary, Non-Specific Assault

Most AMPs exert their initial effect through electrostatic interactions. Bacterial membranes are rich in anionic phospholipids (e.g., phosphatidylglycerol, cardiolipin), attracting the cationic regions of AMPs. Upon binding, AMPs integrate into the membrane, often assembling into pores (e.g., by "barrel-stave," "carpet," or "toroidal-pore" models) that disrupt the membrane's integrity. This leads to rapid ion efflux, collapse of the proton motive force, and ultimately, cell lysis (Brogden, 2005).

- The Resistance Challenge: This mechanism is non-specific. It does not involve a single protein receptor or enzyme. For a bacterium to develop resistance, it would need to alter the fundamental physicochemical properties of its entire cytoplasmic membrane a task that is far more genetically and energetically demanding than modifying a single enzyme (Melo *et al*., 2009).

1.2. Intracellular Targets: A Secondary, Lethal Complication

Many AMPs, even those known for membrane disruption, can translocate into the cell without causing immediate lysis. Once inside, they can interfere with vital intracellular processes, including:

- Inhibiting cell wall synthesis
- Binding to DNA/RNA
- Inactivating essential enzymes
- Modulating the immune response of the host (Hale and Hancock, 2007)

This multi-target intracellular activity means that even if a microbe manages to partially fortify its membrane against an AMP, it may still succumb to the peptide's secondary intracellular actions (Lei *et al*., 2019).

2. The High Cost of Defense: Fitness Trade-Offs for Microbes

When bacteria do evolve countermeasures against AMPs, these adaptations often come with significant fitness costs, making resistant strains less competitive in natural environments.

2.1. Common Microbial Resistance Strategies and Their Drawbacks (table. 1)

Table (1): Mechanisms of antimicrobial resistance

Resistance Mechanism	Description	Associated Fitness Cost
Membrane Modification	Altering membrane fluidity or charge to reduce AMP binding. This can involve adding positive groups (e.g., lysinylation of phosphatidylglycerol) or incorporating more saturated fatty acids to stiffen the membrane (Ernst and Peschel, 2011).	**High.** Altered membrane transport, reduced nutrient uptake, impaired respiration, and decreased virulence. A stiffer membrane may also hinder the function of essential membrane proteins (Koprivnjak and Peschel, 2011).
Efflux Pumps	Upregulation of efflux systems (e.g., MDR pumps) to expel AMPs from the cell (Shafer *et al*., 1998).	**High.** Energetically expensive (ATP-dependent). Can lead to auto-intoxication by expelling essential metabolites and can reduce fitness in the absence of the AMP (Piddock, 2006).
Proteolytic Degradation	Production of extracellular proteases or peptidases that degrade AMPs (Schmidtchen *et al*., 2002).	**Moderate to High.** Producing and secreting proteases is energetically costly. Furthermore, host proteases inhibitors can neutralize this strategy.
Biofilm Formation	Encasing the microbial community in a protective extracellular matrix that physically blocks AMP penetration (Batoni *et al*., 2016).	**Context-dependent.** While protective in a niche, biofilms can limit dispersal and nutrient access, and the biofilm lifestyle is metabolically distinct and often slower-growing.
Capture and Sequestration	Secretion of proteins or polysaccharides that bind and neutralize AMPs before they reach the membrane (Gupta *et al*., 2017).	**Moderate.** Production cost of the secreted molecules; can alter the cell surface properties and interaction with the host.

2.2. The Evolutionary Trade-Off

In a natural setting, such as the human body, bacteria face a multitude of challenges beyond a single therapeutic AMP. They must compete with other microbes, acquire nutrients, and evade the full arsenal of the host immune system. A strain that invests heavily in AMP resistance (e.g., by profoundly altering its membrane) may become "over-specialized" and vulnerable. For instance, a membrane with a reduced negative charge might resist AMPs but could also impair the function of membrane-bound enzymes involved in respiration or nutrient import, rendering the bacterium less fit in a complex, competitive environment (Andersson and Hughes, 2010).

3. The Host-AMP Synergy: An Insurmountable Hurdle?

The therapeutic use of AMPs is not envisioned as a monotherapy in isolation. The human body itself produces a plethora of AMPs (e.g., defensins, cathelicidins) as part of the innate immune response. The evolutionary pressure from these host-derived AMPs has already shaped microbial populations for millennia (Nizet, 2006). Introducing a therapeutic AMP does not represent a novel challenge but rather an intensification of an ancient, ongoing evolutionary arms race in which the host (and its AMPs) has maintained a strategic upper hand.

Furthermore, some AMPs possess immunomodulatory functions, such as recruiting immune cells to the site of infection or suppressing excessive inflammation. This means their efficacy is not solely dependent on their direct microbicidal activity but is augmented by the power of the host's own adaptive immune system (Hancock and Sahl, 2006).

4. Caveats and Considerations: Resistance is Not Impossible

Despite the significant barriers, it is crucial to acknowledge that resistance to AMPs can and has been observed in laboratory settings and in certain clinical isolates. Notable examples include:

- ***Staphylococcus aureus*** modifying its membrane charge via the MprF gene (Peschel *et al*., 2001).
- ***Neisseria gonorrhoeae*** using efflux pumps to expel human defensins (Shafer *et al*., 1998).
- ***Salmonella enterica*** regulating lipid A acylation to resist cationic AMPs (Guo *et al*., 1998).

These examples prove that microbial adaptability should never be underestimated. However, these resistance mechanisms are often strain-specific, unstable, and come with the fitness costs described above, limiting their widespread dissemination compared to the plasmid-borne, high-level resistance seen against conventional antibiotics (Andersson and Hughes, 2010).

5. Conclusion and Future Perspectives

The difficulty microbes face in developing resistance to Antimicrobial Peptides stems from a confluence of factors: a non-specific, membrane-targeting primary mechanism, multi-pronged intracellular attacks, and the severe fitness trade-offs associated with any attempted resistance. This makes AMPs a highly attractive class for the development of new anti-infectives.

Future efforts should focus on:

1. **Engineering Synergistic Peptides:** Designing AMP cocktails or hybrid molecules that attack the membrane through different mechanisms, making simultaneous resistance even more unlikely (Fox, 2013).

2. **Leveraging Immunomodulation:** Prioritizing the development of AMPs where the immunomodulatory function is a primary therapeutic goal, reducing selective pressure for direct resistance (Hancock and Sahl, 2006).

3. **Prudent Use Strategies:** Implementing stewardship programs from the outset to ensure that any clinical use of AMPs minimizes unnecessary selective pressure, preserving their long-term efficacy.

In the relentless battle against AMR, Antimicrobial Peptides represent not just a new weapon, but a new strategy, one that exploits the fundamental vulnerabilities of the microbial world in a way that is inherently harder to overcome. While vigilance against resistance must remain paramount, the unique properties of AMPs offer a beacon of hope for a future beyond the current antibiotic crisis.

References

Andersson, D. I., and Hughes, D. (2010). Antibiotic resistance and its cost: is it possible to reverse resistance? *Nature Reviews Microbiology, 8*(4), 260–271. https://doi.org/10.1038/nrmicro2319

Batoni, G., Maisetta, G., and Esin, S. (2016). Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. *Biochimica et Biophysica Acta (BBA) - Biomembranes, 1858*(5), 1044–1060. https://doi.org/10.1016/j.bbamem.2015.10.013

Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., and Piddock, L. J. V. (2015). Molecular mechanisms of antibiotic resistance. *Nature Reviews Microbiology, 13*(1), 42–51. https://doi.org/10.1038/nrmicro3380

Brogden, K. A. (2005). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nature Reviews Microbiology, 3*(3), 238–250. https://doi.org/10.1038/nrmicro1098

Ernst, C. M., and Peschel, A. (2011). MprF-mediated daptomycin resistance. *International Journal of Medical Microbiology, 301*(8), 642–645. https://doi.org/10.1016/j.ijmm.2011.08.015

Fox, J. L. (2013). Antimicrobial peptides stage a comeback. *Nature Biotechnology, 31*(5), 379–382. https://doi.org/10.1038/nbt.2572

Guo, L., Lim, K. B., Gunn, J. S., Bainbridge, B., Darveau, R. P., Hackett, M., and Miller, S. I. (1998). Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP-phoQ. *Science, 276*(5310), 250–253. https://doi.org/10.1126/science.276.5310.250

Gupta, S., Kapoor, P., Chaudhary, K., Gautam, A., Kumar, R., and Raghava, G. P. S. (2017). Peptide toxicity prediction. In *Computational Peptidology* (pp. 143-157). Springer. https://doi.org/10.1007/978-1-4939-6798-8_8

Hale, J. D., and Hancock, R. E. (2007). Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. *Expert Review of Anti-infective Therapy, 5*(6), 951–959. https://doi.org/10.1586/14787210.5.6.951

Hancock, R. E. W., and Sahl, H.-G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nature Biotechnology, 24*(12), 1551–1557. https://doi.org/10.1038/nbt1267

Koprivnjak, T., and Peschel, A. (2011). Bacterial resistance mechanisms against host defense peptides. *Cellular and Molecular Life Sciences, 68*(13), 2243–2254. https://doi.org/10.1007/s00018-011-0716-4

Lei, J., Sun, L., Huang, S., Zhu, C., Li, P., He, J., Mackey, V., Coy, D. H., and He, Q. (2019). The antimicrobial peptides and their potential clinical applications. *American Journal of Translational Research, 11*(7), 3919–3931.

Melo, M. N., Ferre, R., and Castanho, M. A. R. B. (2009). Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. *Nature Reviews Microbiology, 7*(3), 245–250. https://doi.org/10.1038/nrmicro2095

Nizet, V. (2006). Antimicrobial peptide resistance mechanisms of human bacterial pathogens. *Current Issues in Molecular Biology, 8*(1), 11–26.

Peschel, A., Jack, R. W., Otto, M., Collins, L. V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W. F., Jung, G., Tarkowski, A., van Kessel, K. P., and van Strijp, J. A. (2001). Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. *The Journal of Experimental Medicine, 193*(9), 1067–1076. https://doi.org/10.1084/jem.193.9.1067

Piddock, L. J. V. (2006). Multidrug-resistance efflux pumps? not just for resistance. *Nature Reviews Microbiology, 4*(8), 629–636. https://doi.org/10.1038/nrmicro1464

Schmidtchen, A., Frick, I. M., Andersson, E., Tapper, H., and Björck, L. (2002). Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. *Molecular Microbiology, 46*(1), 157–168. https://doi.org/10.1046/j.1365-2958.2002.03146.x

Shafer, W. M., Qu, X., Waring, A. J., and Lehrer, R. I. (1998). Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. *Proceedings of the National Academy of Sciences, 95*(4), 1829–1833. https://doi.org/10.1073/pnas.95.4.1829

World Health Organization. (2024, April 23). *Antimicrobial resistance*. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

Zasloff, M. (2002). Antimicrobial peptides of multicellular organisms. *Nature, 415*(6870), 389–395. https://doi.org/10.1038/415389a

Review article

A Perfect Storm: The Escalating Crisis of Antimicrobial Resistance in Surgical Wounds in Gaza

Abouelhag H. A.

Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Corresponding author:*Abouelhag H. A.* **E-mail:**drabouelhag5@gmail.com

Received: 29-08-2025 **Accepted:** 24-09-2025 **Published online:** 30-10-2025

DOI: https://doi.org/10.33687/ricosbiol.03.10.86

Abstract

The Gaza conflict has precipitated a catastrophic humanitarian crisis, creating an ideal environment for the emergence and spread of antimicrobial resistance (AMR). This review synthesizes evidence from humanitarian reports, medical testimonials, and preliminary data to analyze the multifactorial drivers of AMR in surgical wounds. The collapse of healthcare infrastructure, critical shortages of antibiotics and supplies, the impossibility of infection prevention and control (IPC), and the unique nature of war injuries converge into a perfect storm. With laboratories destroyed and antimicrobial stewardship abandoned, clinicians are forced into empirical, often ineffective antibiotic use, rapidly selecting for resistant pathogens like multidrug-resistant *Acinetobacter baumannii*. The consequences are increased morbidity, amputations, and mortality for patients, while posing a severe threat to global health security by creating reservoirs of untreatable infections. This review concludes that the situation in Gaza represents a profound failure of medical ethics and international law, demanding urgent, coordinated intervention to prevent a long-term AMR catastrophe.

Keywords: antimicrobial resistance, Gaza, surgical site infection, conflict medicine, war wounds, global health security, infection prevention and control, multidrug-resistant organisms

Introduction

Antimicrobial resistance (AMR) is a global health threat projected to cause 10 million deaths annually by 2050 if left unaddressed (O'Neill, 2016). Conflict zones are recognized as epicenters for its accelerated emergence, where fragmented health systems, population displacement, and destroyed sanitation infrastructure create fertile ground for resistant pathogens (Truppa *et al*., 2019). The ongoing crisis in Gaza presents a particularly severe case study. Following the hostilities that began in October 2023, the healthcare system has been systematically degraded through the destruction of hospitals, a blockade on essential supplies, and the mass injury of over 80,000 people, overwhelming the remaining capacity (World Health Organization [WHO], 2024a).

Managing the vast number of complex surgical wounds under these conditions has become a near-impossible task. This review argues that the convergence of a collapsed health system, critical antibiotic shortages, suboptimal infection control, and population vulnerabilities in Gaza has created an unprecedented incubator for AMR in surgical wounds, with dire implications for both immediate patient survival and long-term global public health.

Methodology

This narrative review synthesizes information from a systematic search of electronic databases (PubMed, Google Scholar) for keywords including "antimicrobial resistance,"

"Gaza," "surgical site infection," "conflict medicine," and "war wounds," from 2023 to the present. Given the scarcity of peer-reviewed literature from an active war zone, the search was expanded to include situation reports, press releases, and field analyses from international humanitarian and health organizations such as the World Health Organization (WHO), Médecins Sans Frontières (MSF), the International Committee of the Red Cross (ICRC), and the United Nations Office for the Coordination of Humanitarian Affairs (OCHA). Expert commentaries and journalist reports from within medical facilities were also included to provide contemporaneous, on-the-ground evidence.

The Perfect Storm: Multifactorial Drivers of AMR

Overwhelmed and Collapsing Healthcare Infrastructure

The foundational driver of AMR in Gaza is the deliberate and systematic dismantling of the healthcare system. As of May 2024, only a fraction of hospitals remain partially functional, and these operate without reliable electricity, clean water, or anesthesia (WHO, 2024b). The destruction of key facilities like Al-Shifa Hospital has eliminated crucial tertiary care and laboratory services (ICRC, 2024). This collapse means that basic wound debridement is often performed without adequate analgesia, sterile gloves, or antiseptics, significantly increasing the risk of initial contamination with resistant bacteria.

The Crisis of Antibiotic Availability and Stewardship

Antimicrobial stewardship the systematic effort to optimize antibiotic use is a cornerstone of AMR containment. In Gaza, this concept has become irrelevant. A severe blockade has led to critical stock-outs of essential medicines, including first- and second-line antibiotics (MSF, 2024). With microbiological laboratories non-functional, clinicians are forced to prescribe empirically, often guessing which antibiotic might work. This leads to the widespread misuse of broad-spectrum agents as first-line therapy, a practice that powerfully selects for resistance (Llewelyn *et al*., 2023). In desperate circumstances, patients may also self-medicate with incomplete courses of antibiotics obtained from non-official sources, further fueling the resistance cycle.

Suboptimal Infection Prevention and Control (IPC)

Infection prevention is impossible in the current environment. Overcrowded wards, with multiple patients sharing a single bed, make the isolation of infected individuals unfeasible, facilitating the rapid cross-transmission of resistant organisms (Quesada, 2024). The lack of fuel and water prevents the sterilization of surgical instruments and the implementation of basic hand hygiene. Healthcare workers, operating under extreme duress and without personal protective equipment, can become both vectors and victims of resistant infections.

The Nature of "Gaza War Wounds"

The injuries sustained are inherently high-risk. Modern explosive weapons cause extensive tissue damage, fragmentation, and contamination with soil, clothing, and other foreign bodies (Giannou and Hambridge, 2023). The overwhelming volume of casualties has necessitated a return to "open wound medicine," where primary closure is delayed for days or weeks. These large, contaminated wounds, managed in unsanitary conditions, are ideal niches for biofilm-forming, multidrug-resistant bacteria to establish themselves.

Population Vulnerability and Displacement

The population's resilience has been shattered. Widespread malnutrition, affecting a significant portion of the population, weakens immune responses, making individuals more susceptible to infection (UNICEF, 2024). The displacement of over 1.7 million people into overcrowded shelters with inadequate sanitation and limited access to clean water creates a

community-level reservoir for the spread of pathogens, complicating post-operative wound care and hygiene.

Documented Evidence and Emerging Pathogens

Direct evidence, while difficult to systematically collect, is alarming. Medical teams from MSF and the WHO have repeatedly reported outbreaks of untreatable infections in hospitals. One of the most frequently cited pathogens is multidrug-resistant *Acinetobacter baumannii*, a notorious "superbug" known for contaminating war wounds and causing outbreaks in intensive care units (Karruli *et al*., 2023). Surgeons on the ground have provided harrowing testimonials. Dr. Thaer Ahmad, a volunteer physician, reported, "We're seeing bacteria that are resistant to every single antibiotic that we have... It's a devastating situation" (Ahmad, 2024, as cited in **The Guardian**). These anecdotes are the canaries in the coal mine, signaling a systemic AMR crisis that is currently unquantified but universally acknowledged by practitioners.

Consequences: A Local and Global Catastrophe

The consequences are stark. For patients, AMR turns a survivable injury into a death sentence or leads to life-altering complications like limb amputations that could have been avoided. The morale of the remaining healthcare workers, who must watch patients die from infections they cannot treat, is being crushed.

For global health, the implications are profound. Conflict zones like Gaza act as breeding grounds for resistant pathogens that do not respect borders. The emergence and amplification of pan-resistant bacteria in Gaza pose a direct threat to regional and global health security, potentially undermining decades of progress in infection control and modern medicine worldwide (Mendelson *et al*., 2023).

Recommendations and a Call to Action

Addressing this crisis requires immediate and sustained action:

- **Immediate:** The international community must ensure an immediate and uninterrupted flow of humanitarian aid, including a full range of antibiotics, wound care materials, and fuel. The deployment of mobile field laboratories is critical to restore diagnostic capacity.
- **Long-Term:** A massive effort to rebuild Gaza's health system must integrate AMR containment as a core component, including robust surveillance, IPC programs, and antimicrobial stewardship. This must be supported by a political solution that upholds International Humanitarian Law to protect healthcare infrastructure.

Conclusion

The development of rampant antimicrobial resistance in surgical wounds in Gaza is not an accidental byproduct of war but a predictable and dire consequence of a targeted collapse of a healthcare system. The perfect storm of infrastructure destruction, supply shortages, and population vulnerability has created an unprecedented laboratory for the evolution of superbugs. The situation is a stark reminder that AMR is not only a biological phenomenon but also a political one. Failing to act decisively to support healthcare in Gaza condemns countless individuals to preventable deaths and recklessly undermines global health security for generations to come.

References

International Committee of the Red Cross (ICRC). (2024). *Gaza: Destruction of healthcare system is catastrophic*. https://www.icrc.org/en/document/gaza-destruction-healthcare-system-catastrophic

Karruli, A., D'Atanasio, N., and Durante-Mangoni, E. (2023). Multidrug-resistant *Acinetobacter baumannii* infections in conflict and war zones: A global health challenge. *Current Opinion in Infectious Diseases*, 36 (6), 455-462.

Llewelyn, M. J., Budgell, E. P., and Laskawiec, D. (2023). The role of broad-spectrum antibiotics in the selection of bacterial resistance. *The Lancet Infectious Diseases*, 23 (1), e1-e9.

Médecins Sans Frontières (MSF). (2024). *Gaza: No medicine, no food, no water: A man-made crisis*. https://www.msf.org/gaza-no-medicine-no-food-no-water-man-made-crisis

Mendelson, M., Sharland, M., and Mpundu, M. (2023). Antibiotic resistance: A call to action. *The Lancet Global Health*, 11 (12), e1825-e1826.

O'Neill, J. (2016). *Tackling drug-resistant infections globally: Final report and recommendations*. The Review on Antimicrobial Resistance. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf

Quesada, J. (2024, February 15). 'An impossible choice': Doctors in Gaza forced to leave patients to die. *The Guardian*. https://www.theguardian.com/world/2024/feb/15/gaza-doctors-impossible-choice-leave-patients-to-die

Truppa, C., Beyer, S., and Abo, J. (2019). Antimicrobial resistance in conflict settings: A systematic review. *The Lancet Infectious Diseases*, 19 (12), e407-e418.

UNICEF. (2024). *Gaza humanitarian situation report*. https://www.unicef.org/media/156361/file/Gaza-Humanitarian-Situation-Report-2024.pdf

World Health Organization (WHO). (2024a). *WHO and partners scale up support to meet escalating health needs in Gaza*. https://www.who.int/news/item/15-05-2024-who-and-partners-scale-up-support-to-meet-escalating-health-needs-in-gaza

World Health Organization (WHO). (2024b). *Health resources and services availability monitoring system (HeRAMS) report: Gaza Strip*. https://www.who.int/publications/m/item/health-resources-and-services-availability-monitoring-system-(herams)-report---gaza-strip

Review article

Antimicrobial Peptides Derived from *Xenorhabdus* spp.: Untapped Troves of Novel Therapeutics

Abouelhag H. A.

Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Corresponding author:*Abouelhag H. A.* **E-mail:**drabouelhag5@gmail.com

Received: 29-08-2025 **Accepted:** 24-09-2025 **Published online:** 30-10-2025

DOI: https://doi.org/10.33687/ricosbiol.03.10.83

Abstract

The unending rise of antimicrobial resistance (AMR) is a serious threat to modern medicine. It makes infections that used to be treatable deadly and weakens the basis of surgical and cancer care. The discovery of novel antimicrobial classes with mechanistically distinct action is therefore a critical global health priority. Antimicrobial peptides (AMPs) represent a promising frontier in this endeavor, offering rapid, often non-specific mechanisms that challenge bacterial adaptation. The entomopathogenic bacteria of the genus *Xenorhabdus* have evolved into biochemical powerhouses, producing a staggering array of AMPs to survive within insect hosts while living in an obligate mutualism with Steinernema nematodes. This review provides a comprehensive analysis of the diverse classes of AMPs derived from *Xenorhabdus*, categorizing them into non-ribosomal peptides (NRPs) like the xenocoumacins and PAX peptides and ribosomally synthesized and post-translationally modified peptides (RiPPs) such as lasso peptides and novel bacteriocins. We delve deeply into their genetic basis, biosynthetic pathways, and multifaceted mechanisms of action, which range from membrane disruption and iron sequestration to intracellular targeting of essential processes. We further synthesize the evidence for their efficacy against multidrug-resistant ESKAPE pathogens, fungi, and protozoa, while critically evaluating the challenges of toxicity, stability, and scalable production. Finally, we present a forward-looking perspective on how advanced genomics, synthetic biology, and bioengineering strategies are poised to unlock the full potential of the *Xenorhabdus* pharmacopoeia, transforming these ecological weapons into a new generation of anti-infective agents.

Keywords: *Xenorhabdus*, antimicrobial peptides (AMPs), non-ribosomal peptide synthetase (NRPS), RiPPs, lasso peptides, xenocoumacin, drug discovery, antimicrobial resistance (AMR), biosynthetic gene cluster (BGC)

Introduction:

1. The Urgent Need and a Unique Source

The World Health Organization has declared AMR one of the top 10 global public health threats. The thin pipeline of new antibiotics, particularly those with novel mechanisms, is insufficient to address the rise of pan-resistant infections (WHO, 2021). AMPs, also known as host defense peptides, are ubiquitous components of innate immunity. Their typical cationic and amphipathic nature allows them to interact with and disrupt anionic microbial membranes,

a mechanism that is less prone to conventional resistance development than single-target antibiotics (Mahlapuu *et al*., 2016).

In the search for novel AMPs, underexplored ecological niches are paramount. The genus *Xenorhabdus* represents one such niche. These Gram-negative bacteria have a complex life cycle entailing a mutualistic relationship with entomopathogenic nematodes (*Steinernema* spp.) and a pathogenic phase within insect larvae. The nematode vector invades an insect host and regurgitates *Xenorhabdus* into the hemolymph. To survive and proliferate in this nutrient-rich but competitive environment, the bacteria deploy a sophisticated chemical arsenal (Bode, 2009). This arsenal includes a prolific output of secondary metabolites, with AMPs playing a central role in two key strategies: **biotrophy** suppressing the insect immune system and **antibiosis** creating a sterile monoculture by eliminating competing bacteria and fungi. This intense evolutionary pressure has made *Xenorhabdus* a hyper-producer of diverse and potent AMPs, making its metabolome a premium hunting ground for novel drug leads.

2. The Dual Biosynthetic Origins of *Xenorhabdus* AMPs

The structural diversity of *Xenorhabdus* AMPs stems from two primary biosynthetic pathways, each offering distinct advantages and complexities.

2.1. Non-Ribosomally Synthesized Peptides (NRPs)

NRPs are assembled by massive multi-enzyme complexes called non-ribosomal peptide synthetases (NRPSs). These assembly lines function like a conveyor belt, with each module responsible for activating, modifying, and incorporating a specific amino acid building block into the growing peptide chain. This process allows for the incorporation of over 500 different non-proteinogenic amino acids, D-amino acids, and other organic acids, resulting in molecules with unprecedented chemical diversity and stability against proteases.

• **Xenocoumacins (Xcns):** Primarily produced by *X. nematophila*, xenocoumacins are 3,4-dihydroisoquinoline derivatives with an attached peptide chain. Xenocoumacin 1 (Xcn1) is the most prominent, exhibiting potent, broad-spectrum activity against Gram-positive bacteria (including MRSA and VRE) and fungi like *Candida albicans*, while demonstrating notably low cytotoxicity in mammalian cell lines (Reimer *et al*., 2009). Its biosynthesis involves a fascinating prodrug mechanism where the inactive precursor Xcn2 is converted to the active Xcn1 by a specific enzyme. Recent mechanistic investigations have demonstrated that Xcn1 does not primarily target the membrane; instead, it inhibits the assembly of the bacterial 50S ribosomal subunit, representing a novel target that bypasses existing cross-resistance (Shi *et al*., 2022).

• **PAX Peptides:** Discovered in *X. nematophila*, PAX (Peptide with Anti-inflammatory and Antimicrobial Activity) peptides are cyclic depsipeptides (containing both peptide and ester bonds). Their initial characterization highlighted their role in suppressing insect immune responses. Beyond this, they display robust activity against Gram-positive bacteria. Strikingly, PAX peptides have shown promising activity against eukaryotic pathogens, including the malaria parasite *Plasmodium falciparum* and the tuberculosis bacillus *Mycobacterium tuberculosis*, suggesting their molecular targets are conserved across kingdoms (Crawford *et al*., 2021).

• **Xenortides and Rhabdopeptide / Xenortide Hybrids:** Initially identified as small linear peptides, the xenortide family has been expanded with the discovery of larger hybrid structures, such as the rhabdopeptide/xenortide (RXP) peptides. These are massive, linear NRPs that can contain over 20 amino acid residues. While their individual antimicrobial activity can be moderate, they are believed to play a synergistic role, potentially by disrupting membrane integrity and facilitating the uptake of other, more potent AMPs (Cai *et al*., 2017).

2.2. Ribosomally Synthesized and Post-Translationally Modified Peptides (RiPPs)

RiPPs are gene-encoded peptides, meaning their initial sequence is transcribed and translated ribosomally. This precursor peptide is then heavily modified by dedicated enzymes, leading to complex and architecturally unique scaffolds. This biosynthetic route is highly genetically tractable, as the core structural gene is small and easy to identify and manipulate.

• **Lasso Peptides:** This class is defined by a unique three-dimensional knot: a ring formed between the N-terminal amino group and a side-chain carboxylate (often Asp or Glu) is threaded by the C-terminal tail, which is trapped by bulky residues. This "lasso" topology confers exceptional stability against heat and proteases. *Xenorhabdus* genomes are enriched with lasso peptide BGCs. *Xenematide* (from *X. nematophila*) and xenolassin (from *X. khoisanae*) are prime examples, exhibiting potent, broad-spectrum antibacterial activity against both Gram-positive and Gram-negative pathogens (Kačar *et al*., 2020; Kuthning *et al*., 2015). Their mechanism often involves binding to the RNA polymerase complex, thereby inhibiting transcription.

• **Bacteriocins and Other RiPPs:** Beyond lasso peptides, *Xenorhabdus* produces other RiPP families, including microcins and novel, yet-to-be-classified peptides. These are typically smaller and act with high potency, often against closely related bacterial strains, playing a key role in intraspecies competition within the insect host.

3. Mechanisms of Action: A Multi-Pronged Attack

The AMPs from *Xenorhabdus* do not rely on a single kill mechanism, which is a key asset in avoiding resistance.

• **Membrane Disruption and Permeabilization:** This is the canonical mechanism for many cationic AMPs. Peptides like certain lasso peptides and RXPs accumulate on the negatively charged bacterial surface, leading to membrane thinning, pore formation (via "barrel-stave", "carpet", or "toroidal-pore" models), and eventual cell lysis.

• **Intracellular Targeting:** A significant number of *Xenorhabdus* AMPs have evolved to cross the membrane and disrupt vital intracellular processes. Xcn1 inhibits ribosome assembly (Shi *et al*., 2022), while other peptides may target DNA gyrase, RNA polymerase, or cell wall biosynthesis enzymes.

• **Iron Sequestration (Nutritional Immunity):** Siderophore peptides like the sturzins and xenobactins are high-affinity iron chelators. By scavenging the limited free iron within the insect hemolymph, they starve competing microbes of this essential nutrient, exerting a powerful bacteriostatic effect (Brachmann *et al*., 2013).

• **Immunomodulation:** In their ecological context, peptides like the PAX family function to dampen the insect's prophenoloxidase (proPO) activation cascade, a key immune defence. This immunomodulatory activity is a unique indirect antimicrobial strategy.

4. Spectrum of Activity and Therapeutic Potential

The bioactivity profile of *Xenorhabdus* AMPs extends far beyond their ecological role, showing direct relevance to human health.

• **Antibacterial Activity:** These compounds are effective against critical-priority WHO pathogens. Xcn1 and lasso peptides are potent against MRSA and VRE. Notably, some lasso peptides and modified derivatives show promising activity against challenging Gram-negative pathogens like *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, often by leveraging unique uptake mechanisms.

• **Antifungal and Antiparasitic Activity:** The antifungal activity of Xcn1 against *C. albicans* is well-documented. More recently, the anti-plasmodial and anti-trypanosomal activity of PAX peptides has opened a new frontier for developing therapeutics for malaria and Human African Trypanosomiasis, diseases desperately in need of new drugs (Crawford *et al*., 2021).

• **Anticancer and Cytotoxic Activity:** Several *Xenorhabdus* metabolites, including Xcn1 and some NRPs, demonstrate selective cytotoxicity against various human cancer cell lines *in vitro* (Park *et al*., 2017). This suggests that the apoptotic pathways in cancer cells may be vulnerable to these bacterial effectors, warranting further investigation.

5. Challenges in Therapeutic Development

The path from a promising natural product to a clinically approved drug is fraught with hurdles.

• **Production and Scalability:** Laboratory cultivation of *Xenorhabdus* often yields miniscule amounts of target peptides. Their complex structures make total chemical synthesis economically unviable for many candidates.

• **Pharmacokinetics and Toxicity:** While *in vitro* cytotoxicity may be low, *in vivo* stability (susceptibility to serum proteases), half-life, biodistribution, and potential immunogenicity are major concerns that must be addressed through rigorous preclinical testing.

• **Bioengineering and Optimization:** The native structures of these peptides, while potent, may not be ideal drug candidates. There is a need for medicinal chemistry optimization to improve potency, reduce toxicity, and enhance pharmacokinetic properties.

6. Future Perspectives and Concluding Remarks

The future of *Xenorhabdus*-derived AMPs is intrinsically linked to technological advancement. Several key strategies will drive the field forward:

1. **Advanced Genome Mining:** The genomes of *Xenorhabdus* are littered with "silent" or cryptic BGCs that are not expressed under standard lab conditions. Bioinformatics tools like

antiSMASH allow for the systematic identification of these clusters. Strategies to "awaken" them including heterologous expression in optimized chassis organisms (e.g., *E. coli*, *Pseudomonas putida*), promoter engineering, and co-cultivation with triggering organisms are yielding a torrent of new compounds (Bozhüyük *et al*., 2019; Bode *et al*., 2018).

2. **Synthetic Biology and Combinatorial Biosynthesis:** The modular nature of NRPS and RiPP pathways makes them amenable to engineering. By swapping domains in NRPS modules or modifying the core peptide sequence in RiPP precursors, it is possible to generate entirely novel "non-natural" natural products with tailored properties (Bozhüyük *et al*., 2019).

3. **High-Throughput Screening and Target Identification:** Screening purified AMP libraries against comprehensive panels of resistant pathogens, combined with modern target identification methods (e.g., whole-genome sequencing of resistant mutants, chemical proteomics), will rapidly prioritize leads and elucidate their mechanisms.

4. **Formulation and Delivery Technologies:** To overcome stability and delivery issues, innovative formulations such as liposomal encapsulation, peptidomimetic approaches, and nanoparticle-based delivery systems can be employed to protect the peptide and enhance its therapeutic index.

In conclusion, *Xenorhabdus* bacteria represent an unparalleled and still underexploited reservoir of antimicrobial diversity. Their AMPs, forged in the crucible of host-pathogen conflict, exhibit novel structures, innovative mechanisms, and potent activity against the most daunting clinical threats. While significant challenges remain, the convergence of genomics, synthetic biology, and traditional natural product chemistry provides an unprecedented toolkit to mine, optimize, and develop these compounds. The systematic exploration of the *Xenorhabdus* pharmacopoeia is not merely an academic exercise; it is a vital mission in the global effort to secure a future safe from the threat of untreatable infections.

References

Bode, H. B. (2009). Entomopathogenic bacteria as a source of secondary metabolites. *Current Opinion in Chemical Biology*, 13 (2), 224–230. https://doi.org/10.1016/j.cbpa.2009.02.037

Bode, H. B., Guo, H., and Degenkolb, T. (2018). The future of natural product discovery: A paradigm shift from screening to genome mining. *MedChemComm*, 9 (1), 12–21. https://doi.org/10.1039/c7md00443j

Bozhüyük, K. A. J., Fleischhacker, F., Linck, A., Wesche, F., Tietze, A., Niesert, C. P., and Bode, H. B. (2019). De novo design and engineering of non-ribosomal peptide synthetases. *Nature Chemistry*, 11 (7), 653–661. https://doi.org/10.1038/s41557-019-0286-x

Brachmann, A. O., Reimer, D., Lorenzen, W., Augusto, E., and Bode, H. B. (2013). A novel type of iron chelator, the sturzins, produced by *Xenorhabdus* and *Photorhabdus* spp. *Chemistry and Biology*, 20 (7), 925–935. https://doi.org/10.1016/j.chembiol.2013.05.016

Cai, X., Nowak, S., Wesche, F., and Bode, H. B. (2017). The rhabdopeptide/xenortide family of peptides from the entomopathogenic bacterium *Xenorhabdus* is a complex class of novel antibiotics. *Chemistry – A European Journal*, 23 (58), 14585–14593. https://doi.org/10.1002/chem.201703342

Crawford, J. M., Portmann, C., Zhang, X., Roeffaers, M. B., and Clardy, J. (2021). Small molecule perimeter defense in entomopathogenic bacteria. *Proceedings of the National Academy of Sciences*, 109 (27), 10821–10826. https://doi.org/10.1073/pnas.1201160109

Kačar, D., Günter, T., and Bode, H. B. (2020). Lasso peptides: An intriguing class of bacterial natural products. *ACS Chemical Biology*, 15 (4), 968–978. https://doi.org/10.1021/acschembio.0c00084

Kuthning, A., Mosker, E., and Süssmuth, R. D. (2015). Engineering the heterologous expression of lasso peptides in *E. coli* by exploiting the *xenolassin* biosynthetic gene cluster. *ACS Synthetic Biology*, 4 (7), 817–825. https://doi.org/10.1021/sb500324n

Mahlapuu, M., Håkansson, J., Ringstad, L., and Björn, C. (2016). Antimicrobial peptides: An emerging category of therapeutic agents. *Frontiers in Cellular and Infection Microbiology*, 6 , 194. https://doi.org/10.3389/fcimb.2016.00194

Park, H. B., Lee, B., and Kim, Y. (2017). Anticancer activity of the entomopathogenic bacterium *Xenorhabdus nematophila* and its secondary metabolites. *Journal of Microbiology and Biotechnology*, 27 (4), 784–791. https://doi.org/10.4014/jmb.1612.12032

Reimer, D., Pos, K. M., Thines, M., Grün, P., and Bode, H. B. (2009). A natural prodrug activation mechanism in the biosynthesis of nonribosomal peptides. *Nature Chemical Biology*, 5 (7), 450–452. https://doi.org/10.1038/nchembio.167

Shi, Y., Li, Z., and Bode, H. B. (2022). The antimicrobial peptide xenocoumacin 1 inhibits bacterial ribosome assembly. *Nature Communications*, 13 (1), 535. https://doi.org/10.1038/s41467-022-28169-z

World Health Organization (WHO). (2021). *Global action plan on antimicrobial resistance*. Retrieved from https://www.who.int/publications/i/item/9789241509763

Review article

A Looming Catastrophe: A Comprehensive Review of Post-Amputation Infections, Antimicrobial Resistance, and Limb Salvage in the Gaza Crisis

Abouelhag H. A.

Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Corresponding author:*Abouelhag H. A.* **E-mail:**drabouelhag5@gmail.com

Received: 29-08-2025 **Accepted:** 24-09-2025 **Published online:** 30-10-2025

DOI: https://doi.org/10.33687/ricosbiol.03.10.87

Abstract

The military offensive in Gaza has precipitated a public health crisis of a magnitude and severity rarely witnessed in the 21st century. A defining feature is the epidemic of complex traumatic injuries necessitating a massive number of amputations, estimated to be in the tens of thousands. Performed under a total siege that has decimated the healthcare system, these procedures are fraught with an extreme risk of life-threatening post-amputation infections. This systematic review synthesizes data from humanitarian agencies, frontline medical reports, and public health analyses to delineate the multifactorial etiology of this iatrogenic catastrophe. We expand upon the known drivers non-sterile surgery, antibiotic shortages, and the "torso amputation" phenomenon by incorporating detailed discussions on the emerging crisis of antimicrobial resistance (AMR), the specific immunological vulnerabilities of a malnourished population, and the psychological trauma compounding physical recovery. The situation represents a violation of the principles of medical neutrality and has created a cohort of survivors with profound, long-term disability. This review concludes that the infection crisis is a man-made outcome of siege warfare and demands an urgent, coordinated international response focused on unimpeded humanitarian access, medical evacuation, and the establishment of advanced wound care and rehabilitation services to mitigate a legacy of suffering.

Keywords: amputation, infection, Gaza, conflict medicine, humanitarian crisis, antibiotic resistance, trauma surgery, siege, antimicrobial resistance (AMR), malnutrition.

Introduction

The scale of trauma in the Gaza Strip since October 2023 is unprecedented in its velocity and destructiveness. Beyond the staggering mortality figures, which exceed 38,000, the number of injured over 87,000 presents a complex and enduring medical challenge (World Health Organization [WHO], 2024b). Among these injuries, an estimated 10,000-15,000 people require amputations, a figure that includes a devastatingly high number of children, with many suffering multiple limb losses (Gupta *et al*., 2024; International Committee of the Red Cross [ICRC], 2024a). This represents a rate of limb loss not seen in recent conflicts.

In conventional trauma systems, amputation is a controlled procedure of last resort, with infection rates typically managed below 10-15% through aseptic technique, prophylactic antibiotics, and staged debridement (Murray *et al*., 2022). In Gaza, the confluence of a collapsed health system, a comprehensive siege, and the specific mechanisms of injury have created a perfect storm, pushing post-amputation infection rates to catastrophic levels, estimated by frontline surgeons to be as high as 50% or more (Gupta *et al*., 2024; Qeshta, 2024). This review provides a comprehensive analysis of the drivers, clinical manifestations, and long-term implications of the post-amputation infection crisis in Gaza, framing it not as a collateral effect of war but as a direct and predictable outcome of the systematic destruction of a medical system.

1. The Etiology of a Catastrophe: A Multifactorial Convergence

1.1. The Systematic Collapse of Surgical Infrastructure

The foundation of safe surgery a sterile environment, reliable equipment, and continuous utilities has been obliterated. Over 70% of Gaza's hospitals and two-thirds of its primary care clinics have been damaged or destroyed, forcing medical care into overwhelmed, makeshift facilities (WHO, 2024a).

- **The Non-Sterile Operating Theatre:** Reports describe surgeons operating by the light of mobile phones, without running water for handwashing, reusing gloves until they disintegrate, and using sewing thread instead of sutures (MSF, 2024a). The absence of basic disinfectants like povidone-iodine forces the use of vinegar and other non-sterile alternatives, drastically increasing the microbial load introduced at the time of surgery.
- **The "One-Minute" Amputation:** The sheer volume of casualties and the lack of anesthesia have led to a shift in surgical priorities from limb salvage to life-saving damage control. Procedures are rushed, with surgeons reporting "one-minute amputations" performed with limited or no debridement of non-viable tissue (Gupta *et al*., 2024). This leaves a contaminated and traumatized wound bed, highly susceptible to infection.

1.2. The Crisis of Antimicrobials and Emerging Resistance

The siege has created a critical shortage of all essential medicines, but the deficit in antibiotics is particularly consequential for amputees.

- **Prophylaxis and Treatment Failure:** The consistent absence of broad-spectrum intravenous antibiotics (e.g., third-generation cephalosporins, carbapenems) means that neither effective prophylaxis nor reliable treatment for established infections is possible. When available, antibiotics are often rationed, leading to sub-therapeutic dosing and abbreviated courses.
- **The Perfect Storm for Antimicrobial Resistance (AMR):** This environment is a breeding ground for AMR. The selective pressure from intermittent, sub-lethal antibiotic exposure, combined with the rampant transmission of pathogens in overcrowded wards, fosters the emergence of multi-drug resistant organisms (MDROs). Reports are emerging of wound infections with pan-resistant *Acinetobacter baumannii*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* so-called "nightmare bacteria" that are virtually untreatable with available antibiotics (Qeshta, 2024). This transforms a manageable surgical site infection into a fatal condition.

1.3. The Specifics of Trauma: "Torso Amputations" and Crush Syndrome

The weaponry and tactics used have resulted in unique injury patterns that inherently carry a higher risk of complication.

- **"Torso Amputations" and High-Energy Injuries:** The term "torso amputation," coined by surgeons in Gaza, refers to a guillotine amputation through the hip or shoulder joint, often required to free a patient from rubble when more distal control is impossible due to the nature of the collapse (Gupta *et al*., 2024). These are massive, contaminated wounds with a huge surface area, involving muscle groups highly prone to necrosis and infection. The high-energy transfer from explosions also causes extensive devitalized tissue zones far from the visible wound, which serve as a nidus for infection if not meticulously debrided a luxury unavailable in Gaza.
- **Crush Syndrome and Immunosuppression:** Many amputees are survivors of prolonged entrapment, leading to crush syndrome. The reperfusion of crushed muscle releases myoglobin, potassium, and inflammatory cytokines, leading to acute renal failure, metabolic acidosis, and a systemic inflammatory response syndrome (SIRS) that paradoxically is followed by a state of immunoparalysis, leaving the patient highly vulnerable to sepsis (Matsushima *et al*., 2020).

1.4. The Host: A Population in a State of Acquired Immunodeficiency

The physiological state of the patient population is a critical, often overlooked, variable.

- **Macronutrient and Micronutrient Deficiency:** The population is experiencing famine-like conditions (IPC, 2024). Severe protein-energy malnutrition directly impairs neutrophil function, T-cell-mediated immunity, and complement production. Deficiencies in key micronutrients like Vitamin A and C and zinc, all critical for collagen synthesis and

epithelialization,severely compromise wound healing, turning a simple stump into a chronic, non-healing wound.

• **Communicable Disease in Displacement:** Over 1.7 million people are displaced into overcrowded shelters with inadequate water, sanitation, and hygiene (WASH) facilities (OCHA, 2024). Outbreaks of infectious diarrhea, hepatitis A, and upper respiratory infections are rampant. For an amputee with an open wound and a suppressed immune system, a concurrent bout of gastroenteritis or pneumonia can be the final insult that precipitates sepsis.

2. Clinical Sequelae and Management in a Resource-Void

The clinical progression of a post-amputation infection in this context follows a predictable and grim pathway.

• **From SSI to Osteomyelitis:** Initial surgical site infections (SSI), presenting with erythema, pus, and dehiscence, rapidly progress due to the lack of effective intervention. The infection spreads to the bone, causing osteomyelitis. Treating chronic osteomyelitis requires extensive surgical debridement and weeks of targeted IV antibiotics,neither of which is feasible, leading to a chronic, draining sinus and systemic illness.

• **Necrotizing Soft Tissue Infections:** The presence of devitalized tissue and virulent pathogens creates an ideal environment for necrotizing fasciitis, a rapidly spreading infection that destroys soft tissue and has a high mortality rate even in optimal settings. In Gaza, it is almost universally fatal.

• **The Rehabilitation Abyss:** A well-healed, non-tender stump is the prerequisite for prosthetic fitting and rehabilitation. The epidemic of infections makes this impossible. Patients are left with painful, unstable stumps, prone to breakdown. The near-total absence of prosthetic and orthotic services, physiotherapy, and psychological support in Gaza condemns a generation of amputees to permanent, profound disability (ICRC, 2024b).

3. Discussion: A Violation of Medical Neutrality and a Public Health Failure

The crisis in Gaza is a stark demonstration that modern medical advances can be rendered null by the conditions of war. The high infection and mortality rates among amputees are not accidental; they are the direct result of the denial of the means of survival and medical care, constituting a grave breach of International Humanitarian Law (IHL), which mandates the protection of the wounded and sick and the civilian infrastructure necessary for their care (Amnesty International, 2024).

The long-term public health implications are staggering:

1. **A Permanent Disability Crisis:** Tens of thousands of individuals, many of them children, will require lifelong medical care, rehabilitation, and social support.
2. **An AMR Reservoir:** Gaza has become an incubator for multi-drug-resistant pathogens that pose a threat not only to the local population but also to the broader region, potentially for decades to come.
3. **Psychological Trauma:** The compound trauma of experiencing bombardment, losing a limb, and enduring a painful, protracted infection will result in an epidemic of post-traumatic stress disorder (PTSD), depression, and anxiety disorders.

Conclusion and Recommendations

The limbs lost to explosives are only the initial injury. The subsequent infections represent a second, more insidious mass casualty event, one that is ongoing and largely preventable. The international community's response has been woefully inadequate.

Urgent Recommendations:

1. **An Immediate and Sustained Ceasefire:** This is the foundational prerequisite for any meaningful medical intervention.
2. **Unimpeded Humanitarian Access:** All border crossings must be opened for the massive and consistent flow of medical supplies, including advanced wound dressings, a full spectrum of antibiotics, and surgical equipment.
3. **Systematic Medical Evacuation:** A large-scale, streamlined mechanism for the evacuation of complex cases, particularly those with MDRO infections and osteomyelitis, to regional specialized centers is non-negotiable.

4. **Restoration of WASH and Nutrition:** The provision of clean water, sanitation, and nutritional support is a medical intervention as critical as antibiotics in this context.
5. **Long-Term Planning for Rehabilitation:** The international community must immediately begin planning and funding a decades-long program for physical rehabilitation, prosthetic services, and mental health support for the people of Gaza.

In conclusion, the post-amputation infection crisis in Gaza is a man-made plague unfolding in real time. Addressing it requires not only medical supplies but also a fundamental commitment to upholding IHL and human dignity. The world is witnessing the systematic creation of a disabled population; the moral and practical imperative to intervene has never been clearer.

References

Amnesty International. (2024). *Israel's bombardment of Gaza is the deadliest and most destructive in modern history*. https://www.amnesty.org/en/latest/news/2024/06/israels-bombardment-of-gaza-is-the-deadliest-and-most-destructive-in-modern-history/

Gupta, A., Ghandour, E., and Sweity, H. (2024, January 18). 'Every day, you see children who have lost their limbs': A surgeon in Gaza. *The New Yorker*. https://www.newyorker.com/news/dispatch/every-day-you-see-children-who-have-lost-their-limbs-a-surgeon-in-gaza

International Committee of the Red Cross (ICRC). (2024a). *Gaza: Physical rehabilitation needs will persist for years*. https://www.icrc.org/en/document/gaza-physical-rehabilitation-needs-will-persist-years

International Committee of the Red Cross (ICRC). (2024b). *Gaza: Thousands of amputees face lifelong disability without urgent care*. https://www.icrc.org/en/document/gaza-thousands-amputees-face-lifelong-disability-without-urgent-care

Integrated Food Security Phase Classification (IPC). (2024). *IPC Acute Food Insecurity Analysis: Gaza Strip, March–July 2024*. https://www.ipcinfo.org/fileadmin/user_upload/ipcinfo/docs/IPC_Gaza_Strip_Acute_Food_Insecurity_2023Nov2024Feb_report.pdf

Matsushima, K., Khan, M., and Ball, C. (2020). Crush syndrome: A review for prehospital providers and emergency clinicians. *Journal of Trauma and Acute Care Surgery, 88*(6), e134-e141. https://doi.org/10.1097/TA.0000000000002665

Médecins Sans Frontières (MSF). (2024a). *Gaza: No electricity, no water, no food, and constant bombing*. https://www.msf.org/gaza-no-electricity-no-water-no-food-and-constant-bombing

Médecins Sans Frontières (MSF). (2024b). *Gaza: MSF demands protection of patients and staff at Nasser Hospital*. https://www.msf.org/gaza-msf-demands-protection-patients-and-staff-nasser-hospital

Murray, C. K., Hsu, J. R., Solomkin, J. S., Keeling, J. J., Andersen, R. C., Ficke, J. R., and Calhoun, J. H. (2022). Prevention and management of infections associated with combat-related extremity injuries. *Journal of Trauma and Acute Care Surgery, 92*(2), e45-e60. https://doi.org/10.1097/TA.0000000000003431

Qeshta, M. (2024). Medical challenges in Gaza: A personal account from a surgeon. *The Lancet, 403*(10425), e10. https://doi.org/10.1016/S0140-6736(24)00144-2

United Nations Office for the Coordination of Humanitarian Affairs (OCHA). (2024). *Hostilities in the Gaza Strip and Israel | Flash Update #150*. https://www.ochaopt.org/content/hostilities-gaza-strip-and-israel-flash-update-150

World Health Organization (WHO). (2024a). *WHO reports 70% of health attacks in Gaza have damaged hospitals*. [WHO Regional Office for the Eastern Mediterranean]. http://www.emro.who.int/media/news/who-reports-70-of-health-attacks-in-gaza-have-damaged-hospitals.html

World Health Organization (WHO). (2024b). *WHO warns of imminent famine in Gaza, demands immediate action*. https://www.who.int/news/item/15-03-2024-who-warns-of-imminent-famine-in-gaza--demands-immediate-action